Market Intel: Breast Imaging Market Driven By AI, Technological Innovation

The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.

Mammogram snapshot of breasts of a female patient on the monitor with undergoing mammography test on the background. Selective focus

Breast cancer is the leading cancer in women globally and incidences continue to rise. To reverse this trend, several companies are focusing their efforts on developing imaging technologies that allow for earlier detection where treatment is more effective and less invasive.

While new developments in breast imaging and biopsy technologies have moved rapidly in recent years, concerns about the effectiveness of population-based screening programs remain. This, in turn, has led to...

More from Business

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.